Evaluation Of Quality Of Life Before And After Treatment With Non-steroidal Anti-inflammatory Drugs In Patients With AxSpA By SF36

ObjectiveTo compare the curative effect of two nonsteroidal antiinflammatory drugs(NSAIDs)in the treatment of axial spondylarthritis(ax-Sp A),and the quality of life of patients with ax-Sp A before and after treatment was evaluated using the 36-item Short Form Health Survey(SF-36).Methods120 patients diagnosed with ax-Sp A were collected in the first Affiliated Hospital of Zhengzhou University from October 2014 to September 2015.They all agreed to be treated with the special drugs and assessed by special scale.Then they all signed the agreement.In the 3 months,double-blind,parallel controlled trial patients were randomized to 200?mg twice daily(bid)imrecoxib,or 200?mg twice daily(bid)celecoxib.They were assessed for the changes of quality of life at enrollment and after three months of NSAIDs therapy by the SF-36 of Chinese edition.The correlation between quality of life and erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),Bath Ankylosing Spondylitis Disease Activity Index(BASDAI),Bath Ankylosing Spondylitis Functional Index(BASFI),SPondylo Arthritis Research Consortium of Canada(SPARCC)was analyzed.ResultsA total of 116 ax-Sp A patients completed the study and 4 patients were lost to follow-up.We used the SF36 scale to assess the quality of life in patients with ax-Sp A before and after 3 months,NSAIDs treatment.The treatment effects were not statistically significant difference between the two drugs(P>0.05).After all the patients were treated with NSAIDs for 3 months,there was statistically significant difference of the physical functioning,role-physical,bodily pain,general health,social functioning,role-emotional(t values were respectively 3.004,5.243,5.989,3.858,2.145,3.960,P<0.05);and there was no statistically significant difference of vitality and mental health(t values were respectively 1.784,1.507,P>0.05).The positively significant correlations had been identified between BASDAI and PF,RP,BP,GH,VT,SF,RE(r were respectively 0.406,0.321,0.463,0.347,0.199,0.276,0.340,P<0.05),while no significant correlation was found between BASDAI and MH(P>0.05).A positively significant correlation had been identified between BASFI and PF,RP,BP,GH,SF,RE,MH(r were respectively 0.523,0.384,0.329,0.193,0.367,0.242,0.214,P<0.05),while no significant correlation was found between BASFI and VT(P>0.05).The overall assessment of patients was positively correlated with PF,RP,BP,GH,SF,RE and MH(P<0.05).The ESR was positively correlated with SF,RE(P<0.05);and CRP was positively correlated with SF,MH(P<0.05);and SPARCC was positively correlated with PF(P<0.05).The tragus to wall was positively correlated with PF?GH(P<0.05);lumbar side flexion was positively correlated with SF(P<0.05);finger and ground distance was positively correlated with SF(P<0.05);and intermalleolar distance was positively correlated with PF,BP,SF,RE(P<0.05).BASDAI and BASFI were the important influence factors of PF(P<0.05);and BASDAI was the important influence factor of BP,GH,VT,RE(P<0.05);BASFI was the important influence factor of RP,SF,MH(P<0.05).Conclusion1.Non-steroidal anti-inflammatory drugs can improve the quality of life of the ax-SpA patients.Imrecoxib and celecoxib have the equivalent curative effect.2.The SF36 scale can reflect the changes in the quality of life of patients with ax-Sp A.The SF36 can be used to assess the quality of life before and after treatment of patients with SpA.